WuXi AppTec acquisition enhances its biometrics services for clinical development6 May 2019
Acquisition will help customers to shorten time-to-market of new drugs.
WuXi AppTec has acquired Pharmapace, a US-based clinical research services company with expertise of providing high-quality biometrics services for all phases of clinical trials, regulatory submissions, and post-marketing support. Upon the closing of this acquisition, Pharmapace will become a wholly-owned subsidiary of WuXi Clinical - the clinical CRO arm of WuXi AppTec - and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical's other clinical development services.
Founded in 2013 in San Diego, California, Pharmapace provides a full range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing with clients in North America, Europe and Asia. With this acquisition, WuXi Clinical expanded its biometrics capabilities in the US and Europe. By integrating Pharmapace and WuXi Clinical China based biometrics teams, the company will be able to provide its global customers with efficient and cost-effective biometrics service essentially round the clock.
With the addition of Pharmapace, WuXi Clinical collectively has over 850 employees located in China and the US, together with its close partners in Europe, Asia Pacific, the company can provide customers full clinical development services, as well as functional service provider (FSP) worldwide. China's recent regulatory reforms that embrace overseas trial data provide an unprecedented opportunity for innovators around the world to accelerate and integrate clinical development both regionally and globally through the WuXi Clinical organization.
"Pharmapace is excited to join WuXi AppTec, a world-class organization with superior leadership and long history of success, a like-minded focus with a customer-centric approach, as well as a vision to enable every company to discover and develop drugs for the patients around the world. This combination now allows us to leverage WuXi AppTec's vast resources to offer customers a truly global solution from preclinical development to clinical development and regulatory submission," said Dr Larry Shen, President and CEO of Pharmapace.
"We are very pleased to welcome Pharmapace to WuXi AppTec. Larry and his leadership team have built a highly reputable biometrics organization in the US," said Edward Hu, Co-CEO of WuXi AppTec. "This acquisition further enhances WuXi Clinical's drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost effectively provide customers seamless biometrics services globally. Together, we are able to shorten time-to-market of new drugs and to achieve the dream that 'every drug can be made and every disease can be treated'."
Improving gut health with human milk oligosaccharides
17 May 2019
2’-FL a very promising agent for digestive health across various age groups beyond infancy.Read more
Expert forecasts huge growth in Middle East manufacturing
16 May 2019
UAE consumers and insurance companies are willing to pay for highest quality drug products.Read more
Colorcon's breakthrough for direct compression
15 May 2019
New starch-based excipient plays an important role in enhancing the stability of moisture-sensitive APIs.Read more
Legacy plans for lyophilisation boom
14 May 2019
The increase in biologics is driving the growth in demand for lyophilization in vials.Read more
Lessons learned from early EU FMD adopters
13 May 2019
Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.Read more
Catalent achieves global ISO accreditation
12 May 2019
Company is one of the first CDMOs to receive award.Read more
Vibalogics increases capacity with a new 200-L line for virus manufacturing
9 May 2019
Company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with increased volumes.Read more
New SIMCA 16 software for multivariate data analytics
8 May 2019
Makes model data easier to interpret for better process control.Read more
Recipharm launches its end-to-end inhalation offering
7 May 2019
Offers a seamless outsourcing service for inhalation products, including MDIs, DPIs and nasal sprays.Read more
Accessible online courses designed to improve tablet compression tooling
7 May 2019
I Holland launches online training for all levels of pharmaceutical and nutraceutical professionals.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation